Fitlife Brands, Inc.FTLF

FITLIFE BRANDS, INC. is a supplement company peddling creatine blends and branched-chain amino acids under brands like CR5® Professional Creatine Complex and BCAA Stim Free, products that promise "optimum strength" and "professional muscular development" but whose financial footprints are far less chiselled. The company’s latest 10-Q filing for the quarter ended March 31, 2026, shows net income of $1.7 million, operating income of $3.1 million, and a stockholders’ equity of $45.4 million against liabilities of $58.9 million, leaving it with more debt-like obligations than muscle-building guarantees. Cash flow from operations clocked in at $2.5 million, but capex was a big fat zero-because when your core assets are tubs of powder, you don’t need much in the way of machinery to keep the lights on. (source: FTLF 10-Q, 2026-05-14, https://www.sec.gov/Archives/edgar/data/1374328/000143774926016875/ftlf20260331_10q.htm)

The company’s online sales segment grew from 2025 to 2026, but the filing doesn’t quantify the increase-just labels it as "OnlineSalesMember," a label so vague it could double as a gym membership discount code. The product pages for CR5 and BCAA Stim Free lean into the promise of free shipping and "highly soluble" formulas, while the balance sheet quietly carries $21.5 million in inventory, up a mere $16,000 from the prior period-hardly the kind of explosive growth that turns a supplement into a fortune. The company’s DEF 14A insists the board brings "valuable perspectives," but the real value might be in spotting the difference between a creatine blend and a dental platform. (source: FTLF 10-Q, 2026-05-14, https://www.sec.gov/Archives/edgar/data/1374328/000143774926016875/ftlf20260331_10q.htm)

Behind the glossy product shots and the DEF 14A’s management desks CVs, FITLIFE BRANDS, INC. is a company whose financials read like a pre-workout drink that didn’t quite mix: $1.7 million in net income for the quarter, $45.4 million in shareholders’ equity, and $58.9 million in liabilities. The board’s latest additions read like a LinkedIn scavenger hunt, with one director’s background in private equity-backed dental partnerships-a CV stretch so wide it could double as a yoga mat. The proxy promises "enhancing the value of the Company’s brands," but the balance sheet suggests the brands might need more than a management desks pep talk to bulk up. (source: FTLF DEF 14A, 2026-06-26, https://www.sec.gov/Archives/edgar/data/1374328/000143774926021797/ftlf20260619_def14a.htm)

For those tracking the company’s governance theatrics, the latest DEF 14A and DEFA14A filings are the main stage. The board’s CVs include stints at dental platforms and consumer goods strategy roles, but the company’s core business-selling creatine and BCAAs-remains a mystery wrapped in a label so vague it could be a gym membership discount code. The filings themselves are a parade of corporate theatre: the proxy promises "valuable perspectives," while the balance sheet whispers about $21.5 million in inventory and $58.9 million in liabilities. The company’s product pages shout about "free shipping" and "professional muscular development," but the financials suggest the real development is in liabilities, not muscles. (source: FTLF DEFA14A, 2026-06-26, https://www.sec.gov/Archives/edgar/data/1374328/000143774926021807/ftlf20260624d_defa14a.htm)

The company’s SEC filings are a masterclass in how to turn a supplement company into a corporate theatre production. The latest DEF 14A and DEFA14A read like a management desks CV audit, with directors’ backgrounds ranging from dental platforms to consumer goods strategy, but the company’s core business-selling powders that promise "optimum strength"-remains a financial lightweight. The balance sheet shows $45.4 million in shareholders’ equity against $58.9 million in liabilities, while inventory sits at $21.5 million, up a mere $16,000 from the prior period. The product pages for CR5 and BCAA Stim Free promise "free shipping" and "highly soluble" formulas, but the filings suggest the real solubility is in the board’s CVs, not the company’s cash flow. (source: FTLF DEFA14A, 2026-06-26, https://www.sec.gov/Archives/edgar/data/1374328/000143774926021806/ftlf20260624c_defa14a.htm)

If you’re looking for a chart to trade this ticker, good luck: the evidence rail doesn’t supply one, and the company’s filings read like a management desks CV audit rather than a growth story. The latest 10-Q and DEF 14A filings are the main event, and they tell a story of a supplement company whose financials are as chiselled as a pre-workout drink left in the sun. The board promises "enhancing the value of the Company’s brands," but the balance sheet suggests the brands might need more than a management desks pep talk to bulk up. (source: FTLF SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1374328)

The company’s product pages for CR5® Professional Creatine Complex and BCAA Stim Free promise "optimum strength" and "professional muscular development," but the filings suggest the real development is in liabilities, not muscles. The balance sheet shows $45.4 million in shareholders’ equity against $58.9 million in liabilities, while inventory sits at $21.5 million-a figure that’s less "super-charged formula" and more "warehouse full of tubs." The company’s online sales segment grew from 2025 to 2026, but the filing doesn’t say by how much, leaving investors to wonder if the growth is in the segment label or the actual sales. (source: CR5® Professional Creatine Complex product page, https://www.fitlifebrands.com/products/cr5; BCAA Stim Free product page, https://www.fitlifebrands.com/products/bcaa)